{"nctId":"NCT00548691","briefTitle":"Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients","startDateStruct":{"date":"2007-10"},"conditions":["Anemia"],"count":513,"armGroups":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL","interventionNames":["Drug: Ferric Carboxymaltose"]},{"label":"Standard Medical Care (SMC)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard Medical Care (SMC)"]}],"interventions":[{"name":"Ferric Carboxymaltose","otherNames":[]},{"name":"Standard Medical Care (SMC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or Female 18 to 85 years of age\n* NDD-CKD Patients\n* TSAT \\</= 25%\n* Hgb \\</= 11.5\n* Ferritin \\</= 300\n* HD-CKD Patients\n* TSAT \\</= 30%\n* Hgb \\</= 12\n* Ferritin \\</= 500\n\nExclusion Criteria:\n\n* Previous participation in a FCM trial\n* Known Hypersensitivity to FCM\n* History of anemia other that anemia due to chronic renal failure\n* Current history of GI bleeding\n* Received IV Iron within the last 30 Days\n* Anticipated need for surgery\n* Malignancy history\n* AST or ALT greater than normal\n* Received an investigational drug within 30 days of screening\n* Pregnant or sexually active females who are not willing to use an effective form of birth control","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-emergent Serious Adverse Events (SAE's)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":254},"commonTop":[]}}}